Edwards Lifesciences Corporation

Business description

Edwards Lifesciences is a global leader in medical innovations for structural heart disease, operating across Transcatheter Aortic Valve Replacement (TAVR, 74% of 2025 sales), Transcatheter Mitral and Tricuspid Therapies (TMTT, 9%), and Surgical Structural Heart (17%). Following the 2024 spinoff of its Critical Care unit to BD, EW is now a pure-play structural heart company with a dominant position in minimally invasive heart valve replacement.

Key financials

• Price: USD 85.73 (07/17/2026)
• 12-Mo Target: USD 96.00
• Market Cap: USD 49.36B
• CFRA Rating: Buy
• H-Score: 77

Competitive moat

• First-mover and technology leader in TAVR with the Edwards SAPIEN valve family, a market it pioneered and has dominated since 2007 (Europe) and 2011 (U.S.).
• Only company with approved tricuspid valve replacement (Evoque), creating a first-mover advantage in a nascent $2B+ TMTT market by 2030.
• Substantial R&D investment (17.8% of 2024 revenues) sustaining a pipeline of next-generation structural heart innovations.
• Negative net debt and conservative 6% debt/capital structure providing significant strategic flexibility.
• Strong clinical data (EARLY TAVR study) driving earlier disease intervention and expanding the addressable patient population.

Recent developments

• TMTT growth accelerating: EW expects TMTT sales to reach at least $2B by 2030 (from $551M in 2025), fueled by SAPIEN M3 U.S. approval and Evoque tricuspid system.
• Q1 2026 beat and guidance raise: Full-year 2026 guidance raised to 10% constant currency sales growth (from 9%) and adjusted EPS midpoint of $3.00 (+17% Y/Y).
• EARLY TAVR data driving volumes: Clinical evidence supporting earlier aortic stenosis intervention expanding the patient pool.
• FTC blocked JenaValve acquisition (2025): Deal terminated in early 2026; may support better near-term margins by avoiding acquisition-related costs.

Investment risks / red flags

• TAVR competition: Intense competition from Medtronic and Abbott in the core TAVR market could pressure market share or pricing.
• Elective procedure disruptions: Macroeconomic shocks or staffing shortages could delay TAVR/TMTT procedure volumes.
• FTC/regulatory risk: FTC blocking of the JenaValve deal signals heightened antitrust scrutiny on structural heart M&A.
• Valuation premium: P/E of 28.6x on 2026 EPS reflects growth expectations that may be vulnerable to any TAVR/TMTT adoption slowdown.

H-Score signals

• TBI multi factor score: 77
• Strong momentum and value score reflecting structural heart market leadership and growth trajectory.

Theme exposure

• [[health-care-equipment]]
• [[structural-heart]]

Related

• [[Health Care Equipment]]
• [[Abbott Laboratories]]